# Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!

Page: https://stenobird.com/podcast/doc-updates-200053/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more
Text version: https://stenobird.com/podcast/doc-updates-200053/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more.md
Podcast: [DOC Updates](https://stenobird.com/podcast/doc-updates-200053)
Published: 2026-06-30T14:24:00+00:00
Episode link: https://diabetescoreupdate.libsyn.com/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more
Audio file: https://traffic.libsyn.com/secure/diabetescoreupdate/Diabetes_Core_Update_July_2026.mp3?dest-id=159994
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more
Duration seconds: 2070

## Resource

Welcome to the latest episode (July 2026) of DOC Updates , where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates : Aroda V, Buzzetti R, Dalskov S et al. " Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study ." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. " Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial ." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. " CGM Monitoring Benefits Extend to Non-Insulin-Using T2D ." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. " Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial ." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 Salive ME, Tjaden AH, Ames JR, et al. " Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes ." JAMA. Published online June 15, 2026. doi: 10.1001/jama.2026.8492 Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medi…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/doc-updates-200053/efficacy-and-safety-of-cagrisema-retatrutide-cgm-benefits-beyond-t2d-more.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.